| Literature DB >> 28603768 |
Sebastiaan Engelborghs1,2, Ellis Niemantsverdriet1, Hanne Struyfs1, Kaj Blennow3, Raf Brouns4, Manuel Comabella5, Irena Dujmovic6, Wiesje van der Flier7, Lutz Frölich8, Daniela Galimberti9, Sharmilee Gnanapavan10, Bernhard Hemmer11,12, Erik Hoff13, Jakub Hort14,15, Ellen Iacobaeus16, Martin Ingelsson17, Frank Jan de Jong18, Michael Jonsson19, Michael Khalil20, Jens Kuhle21, Alberto Lleó22,23, Alexandre de Mendonça24, José Luis Molinuevo25, Guy Nagels4,26,27, Claire Paquet28, Lucilla Parnetti29, Gerwin Roks30, Pedro Rosa-Neto31,32, Philip Scheltens7, Constance Skårsgard33, Erik Stomrud34, Hayrettin Tumani35, Pieter Jelle Visser36,37, Anders Wallin19, Bengt Winblad38, Henrik Zetterberg3,39, Flora Duits7, Charlotte E Teunissen36.
Abstract
INTRODUCTION: Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform the procedure is among others due to a lack of standards and guidelines to minimize the risk of complications, such as post-LP headache or back pain.Entities:
Keywords: Back pain; Cerebrospinal fluid; Consensus guidelines; Evidence-based guidelines; Headache; Lumbar puncture; Post-LP complications
Year: 2017 PMID: 28603768 PMCID: PMC5454085 DOI: 10.1016/j.dadm.2017.04.007
Source DB: PubMed Journal: Alzheimers Dement (Amst) ISSN: 2352-8729
Fig. 1Risk factors for PLPH (A) and nonspecific headache (B) ranked by magnitude (defined by odds ratio) as reported by the multicenter LP feasibility study [5]. Abbreviations: CI, confidence interval; LP, lumbar puncture; OR, odds ratio; PLPH, post-LP headache.
Procedures to rule out contraindications for LP
| Contraindication for LP | Procedures to rule out contraindications | Required action |
|---|---|---|
Space-occupying lesion with mass effect, increase of intracranial pressure due to increased CSF pressure Posterior fossa mass Arnold-Chiari malformation | Clinical neurological examination | Perform brain CT/MRI scan if Abnormal clinical neurological examination Papilledema (Patient has) reduced consciousness (Patient is) immune compromised (Patient has) previous CNS disease (Patient had) recent seizures |
Anticoagulant medication | Check medication before LP | Can anticoagulants temporarily be discontinued? |
Coagulopathy Uncorrected bleeding diathesis | Recent blood analysis: platelet >40 × 109/L; quick > 50%; INR < 1.5 | Correction possible? |
Congenital spine abnormality | Local inspection | Guidance of LP procedure by fluoroscopy, ultrasound, or CT |
Skin infection at puncture site | Local inspection | Treat skin infection |
Abbreviations: LP, lumbar puncture; CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging; CNS, central nervous system; INR, international normalized ratio.
NOTE. All recommendations are based on level-III evidence.
Fig. 2Risk factors for back pain ranked by magnitude (defined by odds ratio) as reported by the multicenter LP feasibility study [5]. Abbreviations: CI, confidence interval; LP, lumbar puncture; OR, odds ratio.
Fig. 3Lumbar puncture procedure and position of the needle during a lumbar puncture. The procedure involves introducing a needle or its respective introducer at the superior aspect of the inferior spinal process into the subarachnoid space of the lumbar sac, at the L4/L5 level or other level safely (L3/L4) below the spinal cord. The technique is for both atraumatic and cutting bevel needles the same, but when using an atraumatic needle, an introducer is inserted into the interspinal ligament first, after which the smaller atraumatic needle is inserted through the introducer. The introducer should be inserted no more than 2/3 – 1/4 of the total length, depending on the adipose tissue availability. During the procedure, the needle stylet is removed every 2-mm interval to check for flow of CSF. In case a nonrecommended cutting bevel needle is used, it is preferred to hold the bevel in the sagittal plane as this diminishes injury to the dura mater by separating its longitudinal fibers rather than cutting through them and reduces the risk of leakage of CSF after the LP. Abbreviations: CSF, cerebrospinal fluid; LP, lumbar puncture.
Needle characteristics are compared based on needle length, size, and design (systematic literature review 2016 [1])
| Needle | Comparison | Advantages | Disadvantages |
|---|---|---|---|
| Length | Regular (70–90 mm) | Adults | — |
| Long (>90 mm) | Obesity | Challenging approach | |
| Diameter in gauge | Small (≥24G) | Reduced complication rates | Decreased flow rates, increased sampling times |
| Large (≤22G) | Increased flow rates | Increased complication rates | |
| Design | Cutting bevel | Penetration is felt through skin | Increased complication rates. Requires more use of medications and medical assistance, which results in increased costs. |
| Atraumatic | Reduced complication rates | Decreased flow rates, increased sampling times |
Abbreviation: G, gauge.
Needle diameters compared through a systematic literature review [1]
| Conclusions | Diameters of needles compared | Motivations | References |
|---|---|---|---|
| No difference: in needle diameters | 20G versus 22G | No difference: PLPH, complaints, traumatic tap incidence, CSF pressure measurement | |
| 22G versus 25G | No difference: PLPH, complaints, attempts | ||
| 23G versus 25G | No difference: PLPH, low back pain, attempts | ||
| Favors: large-bore diameters | 20G versus 22G versus 24G versus 25G | Reduced: collection times | |
| Favors: small-diameter bores | 18G versus 20G versus 22G versus 24G versus 25G | Lower frequency: PLPH | |
| 18G versus 20G versus 22G versus 24G versus 25G versus 26G versus 27G | Reduced: collection times | ||
| 19G versus 20G versus 22G | Lower frequency: PLPH | ||
| 20G versus 22G | Lower frequency: PLPH, complaints, blood patch rates | ||
| 20G versus 22G versus 23G | Lower frequency: PLPH | ||
| 20G versus 22G versus 25G | Lower frequency: PLPH | ||
| 20G versus 24G | Lower frequency: PLPH | ||
| 22G versus 24G | Lower frequency: PLPH, complaints | ||
| 22G versus 25G | Lower frequency: PLPH, low back pain, complaints | ||
| 22G versus 26G | Lower frequency: PLPH, pain | ||
| 22G versus 29G | Lower frequency: PLPH, | ||
| 25G versus 26G versus 27G | Lower frequency: PLPH |
Abbreviations: G, gauge; PLPH, postlumbar puncture headache; CSF, cerebrospinal fluid.
Fig. 4Schematic representative of lateral (A) and superior (B) aspects of the tips of spinal needles: 1, standard large-bore beveled needle; 2, standard small-bore beveled needle; and 3, atraumatic small-bore needle.
Needle designs compared through a systematic literature review [1]
| Conclusion | Needle designs compared | Motivations | Comments | References |
|---|---|---|---|---|
| Favors: atraumatic needle | Quincke versus Pencan | Lower frequency: PLPH, low back pain | Reduced: PLPH interval | |
| Quincke versus Pencan | Lower frequency: PLPH, post-LP complaints | |||
| Quincke versus Sprotte | Lower frequency: PLPH, post-LP complaints, nausea/vomiting | Availability of atraumatic is less | ||
| Quincke versus Sprotte | Lower frequency: PLPH | |||
| Quincke versus Sprotte versus Whitacre | Lower frequency: PLPH | Fewer cells attached to needle (size of cells are smaller), minor epithelial cells | ||
| Quincke versus Sprotte versus Whitacre | Lower frequency: PLPH | |||
| Quincke versus Whitacre | Lower frequency: PLPH, post-LP complaints | |||
| Questionnaire to medical institutions. Favors: atraumatic needle | Quincke versus Sprotte | Lower frequency: PLPH | ||
| Quincke versus Sprotte versus Whitacre | Lower frequency: PLPH | |||
| No difference: in needle designs | Quincke versus Sprotte versus Whitacre | No difference: flow properties | No influence of the performance of needle designs (on flow properties) | |
| Quincke versus Whitacre | No difference: PLPH, low back pain | Same incidence (of PLPH and low back pain) for both needle designs | ||
| Quincke versus Whitacre | No difference: counts in RBC, leakage | |||
| Yale versus Pencan | No difference: success rates | No influence of the performance of needle designs (on success rates in children) | ||
| Yale versus Sprotte | No difference: PLPH, traumatic taps | Same incidence (of PLPH and traumatic tap) for both needle designs |
Abbreviations: PLPH, postlumbar puncture headache; LP, lumbar puncture; CSF, cerebrospinal fluid; RBC, red blood cell.
Recommendations based on level II-2 and III evidence described by graded risk factors
| Recommended procedure | Risk factors | Grading risk factors | Level of evidence |
|---|---|---|---|
| Rule out contraindications | |||
Brain imaging before LP, in case of an intracranial lesion with mass effect, abnormal intracranial pressure, tonsillar herniation is suspected (based on medical history or neurological examination), recent seizures, impaired consciousness, papilledema | − | III | |
Check platelet and coagulation status: platelet >40 × 109/L; quick >50%; INR <1.5 | Coagulopathy | +/− | III |
Check medication before LP | Anticoagulant medication | +/− | III |
| Patients-related risk factors: | |||
Determine risk profile and inform and reassure patients before and during LP procedure | |||
| Risk factors | |||
Younger age | PLPH, back pain | ++ | II-2, III |
Being female <40 years old | Post-LP complaints | +/− | III |
History of headache | PLPH, back pain | ++ | II-2 |
Fear of post-LP complaints | Post-LP complaints | + | II-2 |
| Less risk | |||
Cognitive deterioration | PLPH, back pain | + | II-2, III |
| Procedure-related risk factors | |||
25G atraumatic needle: small needle atraumatic needle | Post-LP complaints | + | III |
<4 LP attempts | Back pain | ++ | II-2 |
Passive withdrawal | Severe headache | + | II-2, III |
Lateral recumbent position | Post-LP complaints | +/− | III |
Collection up to 30 mL | Headache | + | II-2, III |
Abbreviations: LP, lumbar puncture; INR, International normalized ratio; PLPH, postlumbar puncture headache; G, gauge.
NOTE. Grading the impact on risk factors: + high (mentioned in multicenter LP feasibility study as one of the most important factors that influences post-LP complications), + high (mentioned in multicenter LP feasibility study as factor that influences post-LP complications or reported in other study with high quality evidence), +/− moderate (not detected as risk factor in multicenter LP feasibility study, based on consensus and literature), − low (not detected as risk factor in multicenter LP feasibility study, based on consensus and sparse literature). Level of evidence: II-2 = well-designed cohorts preferably with more than one research group or center (e.g., data of large multicenter LP feasibility study, systematic review); III = consensus evidence based on clinical experience of the two consortia (JPND BIOMARKAPD and BioMS).